Travere Therapeutics Announces Pricing of Public Offering of Common Stock

TVTX 11.08.2024

Full Press ReleaseSEC FilingsOur TVTX Tweets

About Gravity Analytica

Recent News

  • 01.14.2025 - 43rd Annual J.P. Morgan Healthcare Conference
  • 01.13.2025 - Travere Therapeutics Provides Corporate Update and 2025 Outlook
  • 01.10.2025 - Prakhar Agrawal

Recent Filings

  • 01.22.2025 - 144 Report of proposed sale of securities
  • 01.13.2025 - 8-K Current report
  • 01.13.2025 - EX-99.1 EX-99.1
PDF Version

SAN DIEGO,Nov. 07, 2024(GLOBE NEWSWIRE) --Travere Therapeutics, Inc.(Nasdaq: TVTX) today announced the pricing of an underwritten public offering of 7,812,500 shares of its common stock at a price to the public of$16.00per share. All of the shares are being sold by Travere. The gross proceeds from the offering are expected to be$125.0 million, before deducting the underwriting discounts and commissions and offering expenses. The offering is expected to close onNovember 12, 2024, subject to customary closing conditions. In addition, Travere has granted the underwriters for the offering a 30-day option to purchase up to an additional 1,171,875 shares of its common stock at the public offering price, less the underwriting discounts and commissions.

JefferiesandLeerink Partnersare acting as the joint book-running managers for the offering and Wedbush PacGrow is acting as co-manager.

The shares of common stock described above are being offered by Travere pursuant to a shelf registration statement filed by Travere with theSecurities and Exchange Commission(SEC) that became automatically effective onAugust 1, 2024. A preliminary prospectus supplement and accompanying prospectus related to the offering were filed with theSECand are available on the SEC’s website located athttp://www.sec.gov. A final prospectus supplement and accompanying prospectus related to the offering will be filed with theSECand will be available on the SEC’s website located athttp://www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus related to this offering, when available, may be obtained fromJefferies LLC, Attention:Equity Syndicate Prospectus Department,520 Madison Avenue,New York, NY10022, by telephone at (877) 821-7388, or by email atProspectus_Department@Jefferies.com; or fromLeerink Partners LLC, Attention:Syndicate Department,53 State Street, 40th Floor,Boston, MA02109, or by telephone at (800) 808-7525, ext. 6105, or by email atsyndicate@leerink.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

AboutTravere Therapeutics

AtTravere Therapeuticswe are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow.

Forward Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. These statements may be identified by introductory words such as “may,” “expects,” “plan,” “believe,” “will,” “achieve,” “anticipate,” “would,” “should,” “subject to” or words of similar meaning, or by the fact that they do not relate strictly to historical or current facts. Such forward-looking statements include statements regarding Travere’s expectations with respect to the completion, timing and size of the proposed public offering. For such statements, Travere claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Travere’s expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the proposed offering, and those factors disclosed in Travere’s filings with theSEC, including its Quarterly Report on Form 10-Q for the quarter endedSeptember 30, 2024. These forward-looking statements represent Travere’s judgment as of the time of this release. Travere disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Contact:888-969-7879IR@travere.com

Primary Logo

Source: Travere Therapeutics, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com